Skip to main content

Table 2 Interaction analyses for double-inhibitory KIR and KIR ligand genotypes with TTRF

From: Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab

  TTRF
Line Treatment Genotype Group Number of Events/n 4 yr Fail Rate (95% CI)a % Interaction p-value
1 Maintenance KIR2DL1+/C2+ and KIR3DL1+/Bw4+ 17/44 37 (24–54) 0.694
2 Maintenance not KIR2DL1+/C2+ and KIR3DL1+/Bw4+ 11/36 34 (19–55)
3 Non-Maintenance KIR2DL1+/C2+ and KIR3DL1+/Bw4+ 10/32 33 (18–54)
4 Non-Maintenance not KIR2DL1+/C2+ and KIR3DL1+/Bw4+ 14/47 31 (19–48)
5 Maintenance Group 1: KIR2DL2+/C1+ and KIR3DL1+/Bw4+ 9/22 45 (24–72) 0.068
6 Maintenance Group 2: not KIR2DL2+/C1+ and KIR3DL1+/Bw4+ 19/58 32 (21–47)
7 Non-Maintenance Group 1: KIR2DL2+/C1+ and KIR3DL1+/Bw4+ 4/23 17 (6–44)
8 Non-Maintenance Group 2: not KIR2DL2+/C1+ and KIR3DL1+/Bw4+ 20/56 38 (26–54)
9 Maintenance KIR2DL3+/C1+ and KIR3DL1+/Bw4+ 12/35 38 (26–54) 0.447
10 Maintenance not KIR2DL3+/C1+ and KIR3DL1+/Bw4+ 16/45 34 (21–51)
11 Non-Maintenance KIR2DL3+/C1+ and KIR3DL1+/Bw4+ 10/37 25 (13–44)
12 Non-Maintenance notT KIR2DL3+/C1+ and KIR3DL1+/Bw4+ 14/42 38 (24–57)
  1. a95% Confidence interval; lines 5-8 (bolded text) had a p-value <0.100 and were analyzed further for associations with outcome